Patents Examined by Michelle S Horning
  • Patent number: 11434497
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: September 6, 2022
    Assignee: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trepanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vezina, Nathalie Landry
  • Patent number: 11433023
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: September 6, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 11426460
    Abstract: The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: August 30, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Peihong Dai, Weiyi Wang
  • Patent number: 11419908
    Abstract: Provided is a platform for of the preparation of improved nucleic acid delivery vehicles, specifically, vehicles having an extended host recognition ability. Further provided are improved vehicles, compositions and uses thereof.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: August 23, 2022
    Assignee: TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP
    Inventors: Ehud Qimron, Ido Yosef, Moran Goren
  • Patent number: 11413336
    Abstract: The present invention concerns methods and compositions for treating or preventing a fungal infection, particularly infection by a Coccidioides species. The invention provides methods and compositions for stimulating an immune response against the fungus. In certain embodiments, the methods and compositions involve a recombinant vaccine.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: August 16, 2022
    Assignees: Board of Regents, The University of Texas System, The University of Massachusetts
    Inventors: Chiung-Yu Hung, Gary Ostroff, Natalia Castro-Lopez
  • Patent number: 11414676
    Abstract: Compositions and methods are disclosed for producing adeno-associated virus (AAV) in insect cells in vitro. Recombinant baculovirus vectors include an AAV Capsid gene expression cassette (Cap), an AAV Rep gene expression cassette (Rep), and a baculovirus homologous region (hr) located up to about 4 kb from a start codon in an AAV expression cassette. Production levels of baculovirus and AAV in insect cells harboring recombinant baculovirus comprising a Cap, a Rep, and an hr are higher compared to controls comprising a Cap and a Rep but no hr. Furthermore, levels of baculovirus and AAV production in insect cells infected with recombinant baculovirus comprising a Cap, a Rep, and an hr are comparatively stable over serial passages of cells, whereas levels of baculovirus and AAV production decline over serial passages of insect cells comprising recombinant baculovirus comprising a Cap and a Rep, but no hr.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: August 16, 2022
    Assignee: Virovek, Inc.
    Inventor: Haifeng Chen
  • Patent number: 11401322
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 2, 2022
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Patent number: 11401307
    Abstract: The invention relates to isolated recombinant analogues of flavivirus E-proteins comprising an analogue of a flavivirus E-protein fusion loop, wherein the analogue of the flavivirus E-protein fusion loop comprises at least one glycosylation site for an N-linked glycan that is not present in a natural flavivirus E-protein fusion loop sequence, wherein the at least one glycosylation site is an N-linked glycosylation sequon (Asn-X-Ser/Thr) and the Asn (N) residue of the sequon occupies any of positions 98-110 (DRGWGNGCGLFGK) of the natural flavivirus E-protein fusion loop amino acid sequence, wherein X is any amino acid residue except proline and Ser/Thr denotes a serine or threonine residue for use in an in vitro method for specific detection of anti-flavivirus antibody, diagnosis of flavivirus infection and/or to investigate exposure to flavivirus.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 2, 2022
    Assignee: Excivion LTD
    Inventor: Peter Laing
  • Patent number: 11389519
    Abstract: This invention is directed to immunogenic composition, conjugates, virus-lie particles (VLP) compositions, vaccines and methods directed to the treatment and/or prevent of infection by Human Papillomavirus.
    Type: Grant
    Filed: June 9, 2019
    Date of Patent: July 19, 2022
    Assignee: Inventprise, LLC
    Inventors: Subhash V. Kapre, Anup K. Datta
  • Patent number: 11357831
    Abstract: The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: June 14, 2022
    Assignees: INSTITUT PASTEUR, ELIGO BIOSCIENCE
    Inventors: David Bikard, Lun Cui, Xavier Duportet, Jesus Fernandez Rodriguez
  • Patent number: 11345896
    Abstract: The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses. The synthetic chimeric poxviruses are well suited for live virus vaccines and pharmaceutical formulations.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 31, 2022
    Inventors: David Evans, Ryan Noyce, Seth Lederman
  • Patent number: 11331383
    Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which Lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: May 17, 2022
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Charles Abrams, Ana-Luisa Reis, Chris Netherton, Linda Dixon, Dave Chapman, Pedro Sanchez-Cordon
  • Patent number: 11324818
    Abstract: The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: May 10, 2022
    Assignee: The Governors of the University of Alberta
    Inventors: Michael Houghton, Abdolamir Landi, Michael Logan, John L. Law, Darren Hockman, Chao Chen
  • Patent number: 11324836
    Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: May 10, 2022
    Assignee: SAIBA AG
    Inventors: Martin Bachmann, Andris Zeltins, Paul Pumpens
  • Patent number: 11319529
    Abstract: This application pertains to methods of isolating virus particles and producing virus vaccine composition comprising subject a biological sample to an anion exchange chromatography and a hydroxyapatite chromatography. The application also pertains to rabies virus vaccine compositions and methods of assessing suitability of a virus vaccine composition or releasing a commercial batch of virus vaccine composition for clinical use.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: May 3, 2022
    Assignees: GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO., LTD., GUANGZHOU YINHEYANGGUANG BIOLOGICS CO., LTD.
    Inventors: Dianlian Liu, Wen Ai, Mingfeng Shen
  • Patent number: 11287423
    Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: March 29, 2022
    Assignee: Biogen MA Inc.
    Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
  • Patent number: 11260122
    Abstract: Methods for providing novel compositions useful as influenza immunogens are provided. The compositions enable a host response to immunogen sites normally not recognized by a host. The novel immunogens can be used as vaccines or to develop antibodies.
    Type: Grant
    Filed: May 12, 2019
    Date of Patent: March 1, 2022
    Assignee: Biological Mimetics, Inc.
    Inventors: Gregory J Tobin, Peter L Nara, George Lin
  • Patent number: 11260123
    Abstract: The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable exctpients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: March 1, 2022
    Assignees: SANOFI PASTEUR LIMITED, SANOFI PASTEUR BIOLOGICS, LLC
    Inventors: Stephen Anderson, Simon Delagrave, John Hamberger, Qinglian Li, Sophia Mundle, Nausheen Rahman
  • Patent number: 11253557
    Abstract: The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: February 22, 2022
    Assignee: ARMATA PHARMACEUTICALS, INC.
    Inventors: Karen Joy Shaw, Sandra P. Morales, Gillian Mearns, Deborah A. Rankin, Frenk Smrekar
  • Patent number: 11253560
    Abstract: The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVA?E3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: February 22, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Jedd Wolchok, Taha Merghoub, Stewart Shuman, Peihong Dai, Weiyi Wang